Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough?
Chunlan Zheng,1,* Xiufen Hu,2,* Li Zhao,1 Minhui Hu,1 Feng Gao3 1Department of Internal Medicine – Section 5, Wuhan Pulmonary Hospital (Wuhan Tuberculosis Control Institute), 2Department of Paediatrics, Tongji Hospital, 3Department of Endocrinology, Union Hospital, Tongji Medical College,...
Saved in:
Main Authors: | Zheng C (Author), Hu X (Author), Zhao L (Author), Hu M (Author), Gao F (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis
by: Wu J, et al.
Published: (2015) -
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
by: Wendy A. Lai, et al.
Published: (2022) -
Sex differences in COVID-19 case fatality: do we know enough?
by: Nabamallika Dehingia, et al.
Published: (2021) -
Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: A qualitative descriptive study
by: Amber Heyd, et al.
Published: (2021) -
Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: A qualitative descriptive study.
by: Amber Heyd, et al.
Published: (2021)